What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A fixed-dose ration combination (12:1) of lopinavir and ritonavir in a vaginal capsule.”In the company’s words, NCT07601074 on ClinicalTrials.gov
- Tested for
- Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
- Main trialPhase 2
- “The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days. The study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.”In the company’s words, NCT07601074 on ClinicalTrials.gov
- Other names
- Lopinavir / ritonavir
Other drugs for Human Papilloma Virus (HPV)
- VP-102Verrica Pharmaceuticals Inc. · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- V503Merck & Co. · Phase 3
- Recombinant Nonavalent Human Papillomavirus VaccineBeijing Health Guard Biotechnology, Inc · Phase 3
- Geniwa gelKTH Biopharma · Phase 2
- 15-valent recombinant human papillomavirus vaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 2
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2027 | A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026